Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of first-class small molecules for neuroregeneration, including synaptogenesis, remyelination, and axonal repair. The company's lead candidate product, PIPE-505, is a small molecule gamma-secretase inhibitor (GSI) for the treatment of mild to moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a range of programs, including PIPE-307, focused on remyelination and axonal repair to address a variety of neurological disorders, including multiple sclerosis.